RecruitingNot ApplicableNCT07685431

Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age

Effects of Alpha-Lipoic Acid Supplementation on Oocyte Quality, Cumulus Cell Mitochondrial Function, and In Vitro Fertilization Outcomes in Infertile Women of Advanced Maternal Age: A Prospective Cohort Study


Sponsor

Kaohsiung Veterans General Hospital.

Enrollment

60 participants

Start Date

Jun 11, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. Thirty participants will receive oral ALA 600 mg/day for two months before their IVF cycle, and thirty will proceed directly to IVF without supplementation. The study will compare oocyte and embryo quality, cumulus cell mitochondrial function and metabolic gene expression, and clinical pregnancy and live birth rates between the two groups.


Eligibility

Sex: FEMALEMin Age: 35 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Alpha-Lipoic Acid (ALA) for people with female infertility due to diminished ovarian reserve. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 35 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAlpha-Lipoic Acid (ALA)

Oral Alpha-Lipoic Acid 600 mg/day for 2 months prior to IVF cycle initiation


Locations(1)

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07685431